Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-02-02 22:58Group 1 - The board of directors and all directors guarantee that the announcement content does not contain any false records, misleading statements, or major omissions, and they bear legal responsibility for the authenticity, accuracy, and completeness of the content [1] - The shareholders' meeting was held on February 2, 2026, at the conference room of Hangzhou Normal University Science Park, Zhejiang Province [2] - The meeting was convened by the board of directors and chaired by Mr. Tong Ziquan, with voting conducted through a combination of on-site and online methods, complying with the Company Law and the company's articles of association [2] Group 2 - All 9 current directors attended the meeting, along with the board secretary and some senior executives [3] - The first resolution discussed was regarding the application for a comprehensive credit limit from the bank and providing guarantees, which was approved by a majority of the voting rights held by shareholders present at the meeting [4] - The voting results for the first resolution were counted separately for small and medium investors [5] Group 3 - The meeting was witnessed by the law firm Guohao Law Firm (Hangzhou) [6] - The lawyers, Song Huiqing and Zhang Yihang, confirmed that the convening and holding procedures of the shareholders' meeting, the qualifications of participants, and the voting procedures complied with relevant laws and regulations, making the voting results legal and valid [7] - This announcement was made by the board of directors of Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. on February 3, 2026 [8]